Dupilumab patent expiry in 2029 is a key question for stakeholders in the pharmaceutical industry.
When does dupilumab's main patent expire?
The primary patent for dupilumab, the active ingredient in Dupixent, is set to expire in 2031. This patent covers the composition of matter [1].
Are there other patents that could affect dupilumab's market exclusivity?
Beyond the composition of matter patent, there are several other patents related to dupilumab, including those covering its use and manufacturing processes [2]. The interplay and expiration dates of these secondary patents can influence when generic or biosimilar versions might become available. Data on specific patent expiry timelines for dupilumab can be found on DrugPatentWatch.com [3].
What is the significance of the 2031 patent expiry for dupilumab?
The expiry of the main composition of matter patent in 2031 is crucial because it marks the point when the exclusivity held by the innovator company, Regeneron Pharmaceuticals, and its partner Sanofi, will end. This typically opens the door for the development and launch of biosimilar versions of dupilumab [1][3].
Could dupilumab face generic competition before 2031?
While the primary patent expires in 2031, challenges to patents or the development of biosimilars using different manufacturing processes or targeting slightly different claims could potentially lead to earlier market entry for competitors. However, extensive litigation is common in these cases, and the ultimate resolution can be complex [2][3].
How does patent expiry impact the price of medications?
Generally, the introduction of biosimilar competition following patent expiry leads to a decrease in drug prices. This is because biosimilars are often developed at a lower cost and compete with the originator product, creating a more competitive market [1].
What is dupilumab used to treat?
Dupilumab is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis [4].
Who are the key companies involved with dupilumab?
Dupilumab was developed by Regeneron Pharmaceuticals and is marketed by Regeneron and Sanofi [4].
What is a biosimilar and how does it relate to patent expiry?
A biosimilar is a biologic product that is highly similar to an already approved biologic medicine, known as the reference product. Biosimilars are approved based on demonstrating that there are no clinically meaningful differences in safety, purity, and potency compared to the reference product [5]. Biosimilar development and approval can only occur after the relevant patents for the reference product have expired or have been successfully challenged [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.regeneron.com/our-science/dupixent
[5] https://www.fda.gov/drugs/biosimilars/what-biosimilar